ClinicalTrials.gg
TerminatedNCT05330455Updated Oct 14, 2026Results posted

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

A Phase 1/2 interventional study of GSK3965193 and Placebo to match GSK3965193 in Hepatitis B, sponsored by GlaxoSmithKline. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated as a strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.

Enrollment
25th of 28
74 · median 163
Started
2022
with 3 others
Phase 1/2
2 of 30
none open now
Registered
26th of 30
by date

Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 25th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 1/2, and was the 26th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, or all of them as a file.
02

Study summary

This Phase 1/2a multiple part study is a first time-in-human (FTIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single (Part 1) and repeat doses (Part 2) of GSK3965193 in healthy participants. Part 3 will evaluate the ability of GSK3965193 to lower hepatitis B virus surface antigen (HBsAg) in participants living with chronic hepatitis B infection (PLWCHB) and will be given the option to subsequently receive treatment with open label bepirovirsen. Part 4 will evaluate the safety and tolerability of combination therapy with GSK3965193 and bepirovirsen and the potential to effect sustained virologic response in PLWCHB.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Bepirovirsen
  • Chronic hepatitis B
  • First-time-in-human
  • GSK3965193
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 74 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Parts 1 and 2: Participants between 18 and 55 years of age inclusive, at the time of signing the .

  • Parts 3 and 4: Participants between 18 and 65 years of age inclusive, at the time of signing the informed consent.
  • Body weight >=50 kilograms (kg) and within the range 18-32 kilograms per square meter (kg/m\^2) (inclusive).
  • Male or female participant: a. Parts 1 and 2: woman of nonchildbearing potential only. b. Parts 3 and 4: woman of nonchildbearing potential or woman of who is not pregnant or breastfeeding and is using a method that is highly effective.
  • Capable of giving signed informed consent.
  • Additional Inclusion Criteria for PLWCHB (Parts 3 and 4).
  • Participants who have documented chronic virus (HBV) infection >=6 months prior to screening.
  • Participants currently receiving stable NA therapy (e.g., tenofovir disoproxil, tenofovir alafenamide, entecavir).
  • Plasma or serum HBsAg concentration >100 IU/mL.
  • Plasma or serum HBV deoxyribonucleic acid (DNA) concentration \<90 IU/mL.
  • Hepatitis B virus e-antigen (HBeAg) positive or negative.
  • (ALT) \<=2 times the (ULN)

Exclusion Criteria:

Exclusion Criteria for Healthy Participants:

  • Positive Hepatitis A virus antibody (HAV Ab immunoglobulin M [IgM]), or positive for HBV, virus (HCV) or (HIV) at screening
  • A current diagnosis of migraine headache
  • ALT >1 times ULN.
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%])
  • interval (QTc) >450 milliseconds (msec)
  • Signs and symptoms suggestive of Coronavirus Disease 2019 (COVID-19)
  • Participants with known COVID-19 positive contacts in the past 14 days.
  • For participants in Part 2A: i. Personal history or family history of peripheral neuropathy. ii. A score ≥4 on the Toronto clinical scoring system for polyneuropathy
  • Current or previous use of tobacco- or nicotine-containing products (for example (e.g.) cigarettes, nicotine patches or electronic devices) within 6 months before screening and/or have a smoking pack history of >5 pack years

Exclusion Criteria for PLWCHB:

  • abnormalities affecting physical or mental health in medical history or on physical examination, aside from chronic HBV infection.
  • Co-infection with or past history of HCV, HIV or Hepatitis D virus (HDV).
  • History of or suspected liver cirrhosis and/or evidence of cirrhosis.
  • Diagnosed or suspected hepatocellular carcinoma.
  • History of within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer).
  • History of vasculitis or presence of symptoms and signs of potential vasculitis [e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause] or history/presence of other diseases Exclusion Criteria for Healthy Participants:
  • Positive Hepatitis A virus antibody (HAV Ab immunoglobulin M [IgM]), or positive for HBV, hepatitis C virus (HCV) or human immunodeficiency virus (HIV) at screening.
  • A current diagnosis of migraine headache
  • ALT >1 times ULN.
  • Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]).
  • Corrected QT interval (QTc) >450 milliseconds (msec).
  • Signs and symptoms suggestive of Coronavirus Disease 2019 (COVID-19).
  • Participants with known COVID-19 positive contacts in the past 14 days.
  • For participants in Part 2A: i. Personal history or family history of peripheral neuropathy. ii. A score ≥4 on the Toronto clinical scoring system for polyneuropathy.
  • Current or previous use of tobacco- or nicotine-containing products (for example (e.g.) cigarettes, nicotine patches or electronic devices) within 6 months before screening and/or have a smoking pack history of >5 pack years

Exclusion Criteria for PLWCHB:

  • Clinically significant abnormalities affecting physical or mental health in medical history or on physical examination, aside from chronic HBV infection.
  • Co-infection with or past history of HCV, HIV or Hepatitis D virus (HDV).
  • History of or suspected liver cirrhosis and/or evidence of cirrhosis.
  • Diagnosed or suspected hepatocellular carcinoma.
  • History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer).
  • History of vasculitis or presence of symptoms and signs of potential vasculitis [e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause] or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
  • History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinaemia, uncontrolled hypertension).
  • History of alcohol or drug abuse/dependence: a. Current alcohol use as judged by investigator to potentially interfere with participant compliance. b. History of or current drug abuse/dependence as judged by the investigator to potentially interfere with participant compliance.
  • History or other evidence of bleeding from esophageal varices.
  • Documented history or other evidence of metabolic liver disease within 1 year of randomization.
  • Personal history or family history of peripheral neuropathy.
  • A score >4 on the Toronto clinical scoring system for polyneuropathy.
  • History of having received or currently receiving any systemic anti-neoplastic (including radiation) or immune-modulatory treatment (including systemic oral , interferon or pegylated interferon) within the 3 months prior to randomization or the expectation that such treatment will be needed at any time during the study.
  • Abnormal and clinically significant 12-lead finding.
  • Currently taking, or taken within 3 months prior to randomization, any drugs (e.g., prednisone), other than a short course of therapy (≤2 weeks) or topical/inhaled steroid use.
  • Participants requiring anti-coagulation therapies.
  • Prior treatment with any oligonucleotide or small interfering RNA (siRNA) within 12 months prior to the first dosing day.
  • Positive test for COVID-19 infection.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4

    Healthy participants received a single dose of placebo oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 2 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 3 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 4 oral solution on Day 1 in Treatment Period 4. Dose 4 of GSK3965193 was higher than Dose 3 and Dose 3 was higher than Dose 2.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4

    Healthy participants received a single dose of GSK3965193 Dose 1 oral solution on Day 1 in Treatment Period 1; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 3 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 4 oral solution on Day 1 in Treatment Period 4. Dose 4 of GSK3965193 was higher than Dose 3 and Dose 3 was higher than Dose 1.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4

    Healthy participants received a single dose of GSK3965193 Dose 1 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 2 oral solution on Day 1 in Treatment Period 2; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 4 oral solution on Day 1 in Treatment Period 4. Dose 4 of GSK3965193 was higher than Dose 2 and Dose 2 was higher than Dose 1.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo

    Healthy participants received a single dose of GSK3965193 Dose 1 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 2 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 3 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of placebo oral solution on Day 1 in Treatment Period 4. Dose 3 of GSK3965193 was higher than Dose 2 and Dose 2 was higher than Dose 1.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8

    Healthy participants received a single dose of placebo oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 6 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 7 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 8 oral solution on Day 1 in Treatment Period 4. Dose 8 of GSK3965193 was higher than Dose 7 and Dose 7 was higher than Dose 6.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8

    Healthy participants received a single dose of GSK3965193 Dose 5 oral solution on Day 1 in Treatment Period 1; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 7 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 8 oral solution on Day 1 in Treatment Period 4. Dose 8 of GSK3965193 was higher than Dose 7 and Dose 7 was higher than Dose 5.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8

    Healthy participants received a single dose of GSK3965193 Dose 5 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 6 oral solution on Day 1 in Treatment Period 2; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 8 oral solution on Day 1 in Treatment Period 4. Dose 8 of GSK3965193 was higher than Dose 6 and Dose 6 was higher than Dose 5.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Experimental
    Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo

    Healthy participants received a single dose of GSK3965193 Dose 5 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 6 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 7 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of placebo oral solution on Day 1 in Treatment Period 4. Dose 7 of GSK3965193 was higher than Dose 6 and Dose 6 was higher than Dose 5.

    Drug: GSK3965193 · Drug: Placebo to match GSK3965193

  • Placebo comparator
    Part 2A: Placebo

    Healthy participants received repeat doses of placebo oral solution twice daily (BID) for 14 days.

    Drug: Placebo to match GSK3965193

  • Experimental
    Part 2A: Cohort 5 - GSK3965193 Dose 9 BID

    Healthy participants received repeat doses of GSK3965193 Dose 9 oral solution BID for 14 days. Dose 9 of GSK3965193 was higher than Dose 4 but lower than Dose 5.

    Drug: GSK3965193

  • Experimental
    Part 2A: Cohort 3 - GSK3965193 Dose 5 BID

    Healthy participants received repeat doses of GSK3965193 Dose 5 oral solution BID for 14 days. Dose 5 of GSK3965193 was higher than Dose 9 but lower than Dose 10.

    Drug: GSK3965193

  • Experimental
    Part 2A: Cohort 4 - GSK3965193 Dose 6 BID

    Healthy participants received repeat doses of GSK3965193 Dose 6 oral solution BID for 14 days. Dose 6 of GSK3965193 was higher than Dose 10 but lower than Dose 7.

    Drug: GSK3965193

  • Experimental
    Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed

    Healthy participants received GSK3965193 Dose 10 oral tablets under fasted condition in Treatment Period 1, followed by GSK3965193 Dose 10 oral tablets under fed condition in Treatment Period 2. Dose 10 of GSK3965193 was higher than Dose 5 but lower than Dose 6.

    Drug: GSK3965193

  • Experimental
    Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted

    Healthy participants received GSK3965193 Dose 10 oral tablets under fed condition in Treatment Period 1, followed by GSK3965193 Dose 10 oral tablets under fasted condition in Treatment Period 2. Dose 10 of GSK3965193 was higher than Dose 5 but lower than Dose 6.

    Drug: GSK3965193

  • Placebo comparator
    Part 3: Cohort 7 - Placebo

    Participants living with chronic hepatitis B infection (PLWCHB) on stable nucleos(t)ide analog (NA) therapy received repeat doses of placebo oral tablets for 28 days. Participants who completed placebo monotherapy were given the option to receive subsequent treatment of optional open label bepirovirsen subcutaneous (SC) injection from Day 43.

    Drug: Placebo to match GSK3965193 · Drug: Bepirovirsen

  • Experimental
    Part 3: Cohort 7 - GSK3965193 Dose 9

    PLWCHB on stable NA therapy received repeat doses of GSK3965193 Dose 9 oral tablets for 28 days. Participants who completed GSK3965193 monotherapy were given the option to receive subsequent treatment of optional open label bepirovirsen SC injection from Day 43. Dose 9 of GSK3965193 was higher than Dose 4 but lower than Dose 5.

    Drug: GSK3965193 · Drug: Bepirovirsen

  • Experimental
    Part 4: Cohort 8 - Placebo + Bepirovirsen

    PLWCHB on stable NA therapy were planned to receive placebo oral tablets plus bepirovirsen SC injection for 28 days. All participants were further planned to continue receiving bepirovirsen SC injection after 28 days.

    Drug: Placebo to match GSK3965193 · Drug: Bepirovirsen

  • Experimental
    Part 4: Cohort 8 - GSK3965193 + Bepirovirsen

    PLWCHB on stable NA therapy were planned to receive GSK3965193 oral tablets plus bepirovirsen SC injection for 28 days. All participants were further planned to continue receiving bepirovirsen SC injection after 28 days.

    Drug: GSK3965193 · Drug: Bepirovirsen

Interventions

  • DrugGSK3965193

    GSK3965193 was administered

  • DrugPlacebo to match GSK3965193

    Placebo to match GSK3965193 was administered

  • Bepirovirsen was administered

07

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Treatment Emergent Adverse Events (STEAEs), and Treatment Withdrawals Due to TEAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.

    Time frame: From the start of study intervention (Day 1) up to 12 weeks

  2. Part 2A: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date.

    Time frame: From the start of study intervention (Day 1) up to 6 weeks

  3. Part 2B: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.

    Time frame: From the start of study intervention (Day 1) up to 9 weeks

  4. Part 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset or worsen date was on or after study intervention start date. Data for the placebo or GSK3965193 monotherapy phase were presented.

    Time frame: From the start of study intervention (Day 1) up to 6 weeks

  5. Part 4: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE would be considered treatment emergent if the AE onset or worsen date was on or after study intervention start date.

    Time frame: From the start of study intervention (Day 1) up to 48 weeks

  6. Part 1: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters

    Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, RBC indices (mean corpuscular volume \[MCV\] and mean corpuscular hemoglobin \[MCH\]), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), blood urea nitrogen (BUN), creatinine, glucose (non-fasting), potassium, sodium, calcium, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator.

    Time frame: At Day 2

  7. Part 2A: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters

    Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.

    Time frame: Up to 21 days

  8. Part 2B: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters

    Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.

    Time frame: Up to 9 weeks

  9. Part 3: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters

    Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

    Time frame: Up to 35 days

  10. Part 3: Number of Participants With Clinically Significant Urinalysis Parameters

    Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

    Time frame: Up to 28 days

  11. Part 4: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters

    Blood samples were planned to be collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was planned to be performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters would be determined by the investigator.

    Time frame: Up to 48 weeks

  12. Part 1: Number of Participants With Clinically Significant Vital Sign Findings

    Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.

    Time frame: Up to 12 weeks

  13. Part 2A: Number of Participants With Clinically Significant Vital Sign Findings

    Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.

    Time frame: Up to 21 days

  14. Part 2B: Number of Participants With Clinically Significant Vital Sign Findings

    Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.

    Time frame: Up to 9 weeks

  15. Part 3: Number of Participants With Clinically Significant Vital Sign Findings

    Vital signs included temperature, SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

    Time frame: Up to 35 days

  16. Part 4: Number of Participants With Clinically Significant Vital Signs Findings

    Vital signs were planned to include temperature, SBP and DBP, pulse and respiratory rate and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings would be determined by the investigator.

    Time frame: Up to 48 weeks

  17. Part 1: Number of Participants With Clinically Significant Electrocardiogram [ECG] Findings

    A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of ECG parameters was determined by the investigator.

    Time frame: Up to 12 weeks

  18. Part 2A: Number of Participants With Clinically Significant ECG Findings

    A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator.

    Time frame: Up to 21 days

  19. Part 3: Number of Participants With Clinically Significant ECG Findings

    A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

    Time frame: Up to 35 days

  20. Part 4: Number of Participants With Clinically Significant ECG Findings

    A 12-lead ECG was planned to be recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters planned to be collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG findings would be determined by the investigator.

    Time frame: Up to 25 weeks

  21. Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 7

    Sensory nerve conduction testing was performed to detect neuropathy in participants. Nerve conduction velocity (NCV) and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25 percent (%) decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 7 was reported.

    Time frame: Baseline and Day 7

  22. Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 14

    Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 14 was reported.

    Time frame: Baseline and Day 14

  23. Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 42

    Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 42 was reported.

    Time frame: Baseline and Day 42

  24. Part 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 15

    Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 15 for the placebo or GSK3965193 monotherapy phase was reported.

    Time frame: Baseline and Day 15

  25. Part 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 29

    Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 29 for the placebo or GSK3965193 monotherapy phase was reported.

    Time frame: Baseline and Day 29

  26. Part 4: Number of Participants With Changes in Sensory Nerve Conduction

    Sensory nerve conduction testing was planned to be performed to detect neuropathy in participants. NCV and nerve conduction amplitude were planned to be determined. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from baseline was planned to be reported.

    Time frame: Baseline up to 29 days

  27. Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3965193 Following Single Dose Administration

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours (h) post-dose

  28. Part 2A: AUC Over the Dosing Interval Tau (AUC[0-tau]) of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods. As the dosing interval Tau was 12 hours, AUC(0-tau) is the same as AUC from time zero to 12 hours after dosing (AUC\[0-12\]).

    Time frame: Pre-dose and 15 minutes (min), 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, and 12 h post-first dose on Day 14

  29. Part 1: Maximum Observed Concentration (Cmax) of GSK3965193 Following Single Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose

  30. Part 2A: Cmax of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14

  31. Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3965193 Following Single Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose

  32. Part 2A: Tmax of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14

  33. Part 1: Apparent Terminal Half-life (T1/2) of GSK3965193 Following Single Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose

  34. Part 2A: T1/2 of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14

  35. Part 3: Maximum Reduction of Serum HBsAg Levels From Baseline

    Blood samples were collected from participants to assess HBsAg levels for the placebo or GSK3965193 monotherapy phase. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Posterior mean and associated 95 percent (%) credible interval were derived for maximum reduction of serum HBsAg levels from Baseline using Bayesian mixed model repeated measures. The data presented are mean referring to posterior mean, with 95% confidence interval referring to 95% credible interval.

    Time frame: From Baseline (Pre-dose on Day 1) up to 6 weeks

  36. Part 4: Number of Participants Achieving Complete Response

    Blood samples were planned to be collected to assess HBsAg and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Complete response is defined HBsAg and HBV DNA below lower limit of quantification (LLOQ) for 6 consecutive months after the planned end of treatment.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Part 2B: AUC(0-inf) of GSK3965193 Following Single Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, and 72 h post-dose

  2. Part 2B: Cmax of GSK3965193 Following Single Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, and 72 h post-dose

  3. Part 3: AUC(0-tau) of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

  4. Part 3: Cmax of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

  5. Part 3: Tmax of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

  6. Part 3: T1/2 of GSK3965193 Following Repeat Dose Administration

    Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

  7. Part 3: Number of Participants With Greater Than or Equal to [≥] 0.5 Times Log International Units Per Milliliters [IU/mL] Reduction From Baseline in Serum HBsAg Levels

    Blood samples were collected from participants at indicated time points to assess HBsAg levels.

    Time frame: From Baseline (Day 1) up to 42 days

  8. Part 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs Among Participants Opting for Optional Bepirovirsen Treatment

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator.

    Time frame: From the start of study intervention up to 54 weeks

  9. Part 3: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters Among Participants Opting for Optional Bepirovirsen Treatment

    Blood samples were planned to be collected to analyze clinical chemistry and hematology parameters: hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium corrected for albumin, creatinine, glucose, potassium, and sodium. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Number of participants with clinically significant clinical chemistry, hematology, and urinalysis parameters were reported. Clinical significance was determined by the investigator.

    Time frame: From Week 7 up to 54 weeks

  10. Part 3: Number of Participants With Clinically Significant Vital Signs Among Participants Opting for Optional Bepirovirsen Treatment

    Vital signs were planned to include temperature and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of vital signs was determined by the investigator.

    Time frame: From Week 7 up to 54 weeks

  11. Part 4: Number of Participants With HBsAg Loss

    Blood samples were collected from participants at indicated time points to assess HBsAg levels. HBsAg loss is defined by two consecutive measurements of HBsAg below the LLOQ any time during the study (on-treatment and post-treatment).

    Time frame: Up to 48 weeks

08

Results

Posted Jun 16, 2026

Participant flow

The study was planned to be conducted in 4 parts. Part 1, a crossover study, consisted of 2 cohorts (Cohorts 1 and 2). Part 2 consisted of 2 sub-parts: Part 2A was a parallel group study comprised of 3 cohorts (Cohorts 3, 4, and 5); and Part 2B was a crossover study comprised of 1 cohort (Cohort 6). Part 3 was a parallel group study comprised of 1 cohort (Cohort 7). Part 4 was planned to be a parallel group study comprised of 1 cohort (Cohort 8).

Part 1, Cohort 1: Treatment Period 1
Participant flow — Part 1, Cohort 1: Treatment Period 1
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started222200000000000000
Completed222200000000000000
Not completed000000000000000000
Part 1, Cohort 1: Treatment Period 2
Participant flow — Part 1, Cohort 1: Treatment Period 2
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started222200000000000000
Completed222200000000000000
Not completed000000000000000000
Part 1, Cohort 1: Treatment Period 3
Participant flow — Part 1, Cohort 1: Treatment Period 3
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started222200000000000000
Completed222200000000000000
Not completed000000000000000000
Part 1, Cohort 1: Treatment Period 4
Participant flow — Part 1, Cohort 1: Treatment Period 4
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started222200000000000000
Completed222200000000000000
Not completed000000000000000000
Part 1, Cohort 2: Treatment Period 1
Participant flow — Part 1, Cohort 2: Treatment Period 1
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000022220000000000
Completed000020220000000000
Not completed000002000000000000
Withdrew: Adverse event000002000000000000
Part 1, Cohort 2: Treatment Period 2
Participant flow — Part 1, Cohort 2: Treatment Period 2
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000022220000000000
Completed000022220000000000
Not completed000000000000000000
Part 1, Cohort 2: Treatment Period 3
Participant flow — Part 1, Cohort 2: Treatment Period 3
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000022220000000000
Completed000011220000000000
Not completed000011000000000000
Withdrew: Adverse event000001000000000000
Withdrew: Withdrawal by subject000010000000000000
Part 1, Cohort 2: Treatment Period 4
Participant flow — Part 1, Cohort 2: Treatment Period 4
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000022220000000000
Completed000022220000000000
Not completed000000000000000000
Part 2A, Cohorts 3, 4, 5
Participant flow — Part 2A, Cohorts 3, 4, 5
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000000006674000000
Completed000000004250000000
Not completed000000002424000000
Withdrew: Adverse event000000000121000000
Withdrew: Physician decision000000002303000000
Part 2B, Cohort 6: Treatment Period 1
Participant flow — Part 2B, Cohort 6: Treatment Period 1
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000000000000670000
Completed000000000000660000
Not completed000000000000010000
Withdrew: Physician decision000000000000010000
Part 2B, Cohort 6: Treatment Period 2
Participant flow — Part 2B, Cohort 6: Treatment Period 2
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000000000000660000
Completed000000000000650000
Not completed000000000000010000
Withdrew: Adverse event000000000000010000
Part 3, Cohort 7
Participant flow — Part 3, Cohort 7
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started0000000000000041400
Completed000000000000003400
Not completed0000000000000011000
Withdrew: Ongoing in optional bepirovirsen treatment part at the time of analysis000000000000001900
Withdrew: Sponsor's decision000000000000000100
Part 4, Cohort 8
Participant flow — Part 4, Cohort 8
MilestonePart 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
Started000000000000000000
Completed000000000000000000
Not completed000000000000000000

Outcome measures

PrimaryPart 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Treatment Emergent Adverse Events (STEAEs), and Treatment Withdrawals Due to TEAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.

Time frame:
From the start of study intervention (Day 1) up to 12 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Treatment Emergent Adverse Events (STEAEs), and Treatment Withdrawals Due to TEAEs
ParticipantsPart 1: Cohorts 1 and 2 - PlaceboPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Any TEAE231113010
Any STEAE000000000
Treatment Withdrawals due to TEAEs000001010
PrimaryPart 2A: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date.

Time frame:
From the start of study intervention (Day 1) up to 6 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Any TEAE4644
Any STEAE0000
Treatment Withdrawals due to TEAEs0121
PrimaryPart 2B: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.

Time frame:
From the start of study intervention (Day 1) up to 9 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
ParticipantsPart 2B: Cohort 6 - GSK3965193 Dose 10 FastedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed
Any TEAE31
Any STEAE00
Treatment Withdrawals due to TEAEs00
PrimaryPart 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset or worsen date was on or after study intervention start date. Data for the placebo or GSK3965193 monotherapy phase were presented.

Time frame:
From the start of study intervention (Day 1) up to 6 weeks
Reported as:
Count of participants · Participants
Part 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
Any TEAE24
Any STEAE00
Withdrawals due to TEAEs01
PrimaryPart 4: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE would be considered treatment emergent if the AE onset or worsen date was on or after study intervention start date.

Time frame:
From the start of study intervention (Day 1) up to 48 weeks

No measurements were reported for this outcome.

PrimaryPart 1: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters

Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, RBC indices (mean corpuscular volume \[MCV\] and mean corpuscular hemoglobin \[MCH\]), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), blood urea nitrogen (BUN), creatinine, glucose (non-fasting), potassium, sodium, calcium, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator.

Time frame:
At Day 2
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters
ParticipantsPart 1: Cohorts 1 and 2 - PlaceboPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Hematology000000000
Clinical Chemistry000100000
PrimaryPart 2A: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters

Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Hematology0000
Clinical Chemistry0000
Urinalysis0000
PrimaryPart 2B: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters

Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.

Time frame:
Up to 9 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters
ParticipantsPart 2B: Cohort 6 - GSK3965193 Dose 10 FastedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed
Hematology00
Clinical Chemistry00
Urinalysis00
PrimaryPart 3: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters

Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

Time frame:
Up to 35 days
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
Hematology00
Clinical Chemistry10
PrimaryPart 3: Number of Participants With Clinically Significant Urinalysis Parameters

Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Clinically Significant Urinalysis Parameters
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
Part 3: Number of Participants With Clinically Significant Urinalysis Parameters00
PrimaryPart 4: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters

Blood samples were planned to be collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was planned to be performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters would be determined by the investigator.

Time frame:
Up to 48 weeks

No measurements were reported for this outcome.

PrimaryPart 1: Number of Participants With Clinically Significant Vital Sign Findings

Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsPart 1: Cohorts 1 and 2 - PlaceboPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Part 1: Number of Participants With Clinically Significant Vital Sign Findings000000000
PrimaryPart 2A: Number of Participants With Clinically Significant Vital Sign Findings

Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Part 2A: Number of Participants With Clinically Significant Vital Sign Findings0010
PrimaryPart 2B: Number of Participants With Clinically Significant Vital Sign Findings

Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.

Time frame:
Up to 9 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsPart 2B: Cohort 6 - GSK3965193 Dose 10 FastedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed
Part 2B: Number of Participants With Clinically Significant Vital Sign Findings00
PrimaryPart 3: Number of Participants With Clinically Significant Vital Sign Findings

Vital signs included temperature, SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

Time frame:
Up to 35 days
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
Part 3: Number of Participants With Clinically Significant Vital Sign Findings00
PrimaryPart 4: Number of Participants With Clinically Significant Vital Signs Findings

Vital signs were planned to include temperature, SBP and DBP, pulse and respiratory rate and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings would be determined by the investigator.

Time frame:
Up to 48 weeks

No measurements were reported for this outcome.

PrimaryPart 1: Number of Participants With Clinically Significant Electrocardiogram [ECG] Findings

A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of ECG parameters was determined by the investigator.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Electrocardiogram [ECG] Findings
ParticipantsPart 1: Cohorts 1 and 2 - PlaceboPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Part 1: Number of Participants With Clinically Significant Electrocardiogram [ECG] Findings000000000
PrimaryPart 2A: Number of Participants With Clinically Significant ECG Findings

A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Clinically Significant ECG Findings
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Part 2A: Number of Participants With Clinically Significant ECG Findings0000
PrimaryPart 3: Number of Participants With Clinically Significant ECG Findings

A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.

Time frame:
Up to 35 days
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Clinically Significant ECG Findings
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
Part 3: Number of Participants With Clinically Significant ECG Findings00
PrimaryPart 4: Number of Participants With Clinically Significant ECG Findings

A 12-lead ECG was planned to be recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters planned to be collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG findings would be determined by the investigator.

Time frame:
Up to 25 weeks

No measurements were reported for this outcome.

PrimaryPart 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 7

Sensory nerve conduction testing was performed to detect neuropathy in participants. Nerve conduction velocity (NCV) and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25 percent (%) decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 7 was reported.

Time frame:
Baseline and Day 7
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 7
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
25% decrease in nerve conduction velocity0000
50% decrease in nerve conduction amplitude0010
PrimaryPart 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 14

Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 14 was reported.

Time frame:
Baseline and Day 14
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 14
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
25% decrease in nerve conduction velocity000—
50% decrease in nerve conduction amplitude000—
PrimaryPart 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 42

Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 42 was reported.

Time frame:
Baseline and Day 42
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 42
ParticipantsPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
25% decrease in nerve conduction velocity000—
50% decrease in nerve conduction amplitude000—
PrimaryPart 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 15

Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 15 for the placebo or GSK3965193 monotherapy phase was reported.

Time frame:
Baseline and Day 15
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 15
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
25% decrease in nerve conduction velocity00
50% decrease in nerve conduction amplitude00
PrimaryPart 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 29

Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 29 for the placebo or GSK3965193 monotherapy phase was reported.

Time frame:
Baseline and Day 29
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 29
ParticipantsPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
25% decrease in nerve conduction velocity00
50% decrease in nerve conduction amplitude00
PrimaryPart 4: Number of Participants With Changes in Sensory Nerve Conduction

Sensory nerve conduction testing was planned to be performed to detect neuropathy in participants. NCV and nerve conduction amplitude were planned to be determined. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from baseline was planned to be reported.

Time frame:
Baseline up to 29 days

No measurements were reported for this outcome.

PrimaryPart 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3965193 Following Single Dose Administration

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours (h) post-dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3965193 Following Single Dose Administration
Hours*nanograms per milliliterPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3965193 Following Single Dose Administration1.95 ± 20.317.46 ± 20.2114.50 ± 15.2447.35 ± 15.72147.02 ± 26.27412.52 ± 23.011675.39 ± 29.133207.43 ± 34.82
PrimaryPart 2A: AUC Over the Dosing Interval Tau (AUC[0-tau]) of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods. As the dosing interval Tau was 12 hours, AUC(0-tau) is the same as AUC from time zero to 12 hours after dosing (AUC\[0-12\]).

Time frame:
Pre-dose and 15 minutes (min), 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, and 12 h post-first dose on Day 14
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2A: AUC Over the Dosing Interval Tau (AUC[0-tau]) of GSK3965193 Following Repeat Dose Administration
Hours*nanograms per milliliterPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Day 154.16 ± 18.53123.78 ± 14.85296.23 ± 15.40
Day 1483.76 ± 27.13185.44 ± 31.76—
PrimaryPart 1: Maximum Observed Concentration (Cmax) of GSK3965193 Following Single Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Geometric mean · Nanograms per milliliter
Part 1: Maximum Observed Concentration (Cmax) of GSK3965193 Following Single Dose Administration
Nanograms per milliliterPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Part 1: Maximum Observed Concentration (Cmax) of GSK3965193 Following Single Dose Administration0.26 ± 14.751.05 ± 22.022.24 ± 16.858.43 ± 14.0525.08 ± 11.6581.00 ± 13.38247.21 ± 21.43504.23 ± 24.24
PrimaryPart 2A: Cmax of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14
Reported as:
Geometric mean · Nanograms per milliliter
Part 2A: Cmax of GSK3965193 Following Repeat Dose Administration
Nanograms per milliliterPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Day 110.38 ± 29.1622.93 ± 18.1972.56 ± 22.24
Day 1413.71 ± 10.8428.10 ± 32.46—
PrimaryPart 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3965193 Following Single Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Median · Hours
Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3965193 Following Single Dose Administration
HoursPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3965193 Following Single Dose Administration0.50 (0.5 to 2.0)0.51 (0.3 to 2.0)0.38 (0.3 to 1.0)0.38 (0.3 to 0.5)0.50 (0.3 to 0.5)0.38 (0.3 to 0.5)0.50 (0.5 to 1.0)0.50 (0.3 to 1.0)
PrimaryPart 2A: Tmax of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14
Reported as:
Median · Hours
Part 2A: Tmax of GSK3965193 Following Repeat Dose Administration
HoursPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Day 10.38 (0.3 to 1.0)0.50 (0.3 to 2.0)0.38 (0.3 to 0.5)
Day 140.50 (0.5 to 0.5)0.50 (0.3 to 1.0)—
PrimaryPart 1: Apparent Terminal Half-life (T1/2) of GSK3965193 Following Single Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose
Reported as:
Mean · Hours
Part 1: Apparent Terminal Half-life (T1/2) of GSK3965193 Following Single Dose Administration
HoursPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8
Part 1: Apparent Terminal Half-life (T1/2) of GSK3965193 Following Single Dose Administration7.40 ± 1.7327.17 ± 1.5687.62 ± 1.0617.92 ± 0.8148.26 ± 1.4157.57 ± 0.4437.63 ± 0.5617.57 ± 1.054
PrimaryPart 2A: T1/2 of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14
Reported as:
Mean · Hours
Part 2A: T1/2 of GSK3965193 Following Repeat Dose Administration
HoursPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BID
Day 15.53 ± 0.8715.15 ± 1.1994.26 ± 0.966
Day 145.15 ± 1.1085.52 ± 1.133—
PrimaryPart 3: Maximum Reduction of Serum HBsAg Levels From Baseline

Blood samples were collected from participants to assess HBsAg levels for the placebo or GSK3965193 monotherapy phase. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Posterior mean and associated 95 percent (%) credible interval were derived for maximum reduction of serum HBsAg levels from Baseline using Bayesian mixed model repeated measures. The data presented are mean referring to posterior mean, with 95% confidence interval referring to 95% credible interval.

Time frame:
From Baseline (Pre-dose on Day 1) up to 6 weeks
Reported as:
Mean · Log10 international units per milliliter
Part 3: Maximum Reduction of Serum HBsAg Levels From Baseline
Log10 international units per milliliterPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9
Part 3: Maximum Reduction of Serum HBsAg Levels From Baseline0.075 (0.0512 to 0.0947)0.508 (0.2913 to 0.6924)
PrimaryPart 4: Number of Participants Achieving Complete Response

Blood samples were planned to be collected to assess HBsAg and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Complete response is defined HBsAg and HBV DNA below lower limit of quantification (LLOQ) for 6 consecutive months after the planned end of treatment.

Time frame:
Up to 48 weeks

No measurements were reported for this outcome.

SecondaryPart 2B: AUC(0-inf) of GSK3965193 Following Single Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, and 72 h post-dose

Results for this outcome have not been posted.

SecondaryPart 2B: Cmax of GSK3965193 Following Single Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, and 72 h post-dose

Results for this outcome have not been posted.

SecondaryPart 3: AUC(0-tau) of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

Results for this outcome have not been posted.

SecondaryPart 3: Cmax of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

Results for this outcome have not been posted.

SecondaryPart 3: Tmax of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

Results for this outcome have not been posted.

SecondaryPart 3: T1/2 of GSK3965193 Following Repeat Dose Administration

Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28

Results for this outcome have not been posted.

SecondaryPart 3: Number of Participants With Greater Than or Equal to [≥] 0.5 Times Log International Units Per Milliliters [IU/mL] Reduction From Baseline in Serum HBsAg Levels

Blood samples were collected from participants at indicated time points to assess HBsAg levels.

Time frame:
From Baseline (Day 1) up to 42 days

Results for this outcome have not been posted.

SecondaryPart 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs Among Participants Opting for Optional Bepirovirsen Treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator.

Time frame:
From the start of study intervention up to 54 weeks

Results for this outcome have not been posted.

SecondaryPart 3: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters Among Participants Opting for Optional Bepirovirsen Treatment

Blood samples were planned to be collected to analyze clinical chemistry and hematology parameters: hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium corrected for albumin, creatinine, glucose, potassium, and sodium. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Number of participants with clinically significant clinical chemistry, hematology, and urinalysis parameters were reported. Clinical significance was determined by the investigator.

Time frame:
From Week 7 up to 54 weeks

Results for this outcome have not been posted.

SecondaryPart 3: Number of Participants With Clinically Significant Vital Signs Among Participants Opting for Optional Bepirovirsen Treatment

Vital signs were planned to include temperature and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of vital signs was determined by the investigator.

Time frame:
From Week 7 up to 54 weeks

Results for this outcome have not been posted.

SecondaryPart 4: Number of Participants With HBsAg Loss

Blood samples were collected from participants at indicated time points to assess HBsAg levels. HBsAg loss is defined by two consecutive measurements of HBsAg below the LLOQ any time during the study (on-treatment and post-treatment).

Time frame:
Up to 48 weeks

Results for this outcome have not been posted.

Adverse events

Collected over All-cause mortality, non-serious TEAEs and STEAEs were collected up to 12 weeks for Part 1, 6 weeks for Part 2A, 9 weeks for Part 2B, and 6 weeks in Part 3.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohorts 1 and 2 - Placebo0/16 (0%)0/16 (0%)2/16 (12.5%)
Part 1: Cohort 1 - GSK3965193 Dose 10/6 (0%)0/6 (0%)3/6 (50%)
Part 1: Cohort 1 - GSK3965193 Dose 20/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Cohort 1 - GSK3965193 Dose 30/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Cohort 1 - GSK3965193 Dose 40/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Cohort 2 - GSK3965193 Dose 50/6 (0%)0/6 (0%)3/6 (50%)
Part 1: Cohort 2 - GSK3965193 Dose 60/6 (0%)0/6 (0%)0/6 (0%)
Part 1: Cohort 2 - GSK3965193 Dose 70/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Cohort 2 - GSK3965193 Dose 80/6 (0%)0/6 (0%)0/6 (0%)
Part 2A: Placebo0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 2A: Cohort 5 - GSK3965193 Dose 9 BID0/6 (0%)0/6 (0%)6/6 (100%)
Part 2A: Cohort 3 - GSK3965193 Dose 5 BID0/7 (0%)0/7 (0%)4/7 (57.1%)
Part 2A: Cohort 4 - GSK3965193 Dose 6 BID0/4 (0%)0/4 (0%)4/4 (100%)
Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted0/11 (0%)0/11 (0%)3/11 (27.3%)
Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed0/13 (0%)0/13 (0%)1/13 (7.7%)
Part 3: Cohort 7 - Placebo0/4 (0%)0/4 (0%)2/4 (50%)
Part 3: Cohort 7 - GSK3965193 Dose 90/14 (0%)0/14 (0%)4/14 (28.6%)
Part 4: Cohort 8 - Placebo + Bepirovirsen———
Part 4: Cohort 8 - GSK3965193 + Bepirovirsen———
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPart 1: Cohorts 1 and 2 - PlaceboPart 1: Cohort 1 - GSK3965193 Dose 1Part 1: Cohort 1 - GSK3965193 Dose 2Part 1: Cohort 1 - GSK3965193 Dose 3Part 1: Cohort 1 - GSK3965193 Dose 4Part 1: Cohort 2 - GSK3965193 Dose 5Part 1: Cohort 2 - GSK3965193 Dose 6Part 1: Cohort 2 - GSK3965193 Dose 7Part 1: Cohort 2 - GSK3965193 Dose 8Part 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 FastedPart 2B: Cohort 6 - GSK3965193 Dose 10 FedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + Bepirovirsen
HeadacheNervous system disorders1/162/60/60/60/61/60/60/60/61/64/61/71/41/110/130/42/14——
FatigueGeneral disorders0/160/60/60/60/60/60/60/60/61/62/60/72/40/110/130/43/14——
Brain fogNervous system disorders0/160/60/60/60/60/60/60/60/60/63/60/70/40/110/130/40/14——
TinnitusEar and labyrinth disorders0/160/60/60/60/60/60/60/60/60/62/60/70/40/110/130/40/14——
Post procedural complicationInjury, poisoning and procedural complications0/160/60/60/60/60/60/60/60/62/60/60/70/40/110/130/40/14——
DysgeusiaNervous system disorders0/160/60/60/60/60/60/60/60/60/62/60/70/40/110/130/42/14——
NightmarePsychiatric disorders0/160/60/60/60/60/60/60/60/60/62/60/70/40/110/130/40/14——
DizzinessNervous system disorders0/160/60/60/60/60/60/60/60/61/61/60/70/40/110/130/44/14——
NauseaGastrointestinal disorders0/160/60/60/60/60/60/60/60/60/61/60/71/40/110/130/41/14——
Feeling abnormalGeneral disorders0/160/60/60/60/60/60/60/60/60/60/60/71/40/110/130/40/14——

Baseline characteristics

The study was terminated after completion of Part 3 as a strategic decision. Hence, no participants were enrolled in Part 4.

Age, Customized
Age, Customized(Participants)Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + BepirovirsenTotal
18 to 55 years222235226674673130072
56 to 65 years0000000000000011002
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + BepirovirsenTotal
Female0000000000000004004
Male222235226674674100070
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/PlaceboPart 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/PlaceboPart 2A: PlaceboPart 2A: Cohort 5 - GSK3965193 Dose 9 BIDPart 2A: Cohort 3 - GSK3965193 Dose 5 BIDPart 2A: Cohort 4 - GSK3965193 Dose 6 BIDPart 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/FedPart 2B: Cohort 6 - GSK3965193 Dose 10 Fed/FastedPart 3: Cohort 7 - PlaceboPart 3: Cohort 7 - GSK3965193 Dose 9Part 4: Cohort 8 - Placebo + BepirovirsenPart 4: Cohort 8 - GSK3965193 + BepirovirsenTotal
ASIAN020001020000001100016
BLACK OR AFRICAN AMERICAN00100100011104130013
WHITE20123320656363210045
09

Study locations

14 sites
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Grenoble, 38043, France
  • GSK Investigational Site
    Nantes, 44000, France
  • GSK Investigational Site
    Rennes, 35033, France
  • GSK Investigational Site
    Milan, 20122, Italy
  • GSK Investigational Site
    Monza MB, 20900, Italy
  • GSK Investigational Site
    Daegu, 41944, South Korea
  • GSK Investigational Site
    Pusan, 49241, South Korea
  • GSK Investigational Site
    Seoul, 05505, South Korea
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Cambridge, CB2 2GG, United Kingdom
  • GSK Investigational Site
    London, SW17 0QT, United Kingdom
  • GSK Investigational Site
    London, W2 1NY, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2025, 37 months.

Results were first posted in Jun 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2022
First posted
Apr 15, 2022
StartActual
Apr 14, 2022
Primary completionActual
May 19, 2025
CompletionActual
Apr 8, 2026
Results first posted
Jun 16, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, oversight details and site details
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05330455
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Apr 14, 2022
Primary completion
May 19, 2025
Completion
Apr 8, 2026
Results posted
Jun 16, 2026
Last update
Oct 14, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion